Text Size

Nabilone & Marijuana Addiction

This study has been completed.
Sponsor:
Information provided by:
University of British Columbia
ClinicalTrials.gov Identifier:
NCT01025700
First received: December 2, 2009
Last updated: February 16, 2011
Last verified: February 2011
History of Changes
  Purpose

Safety of Nabilone in reducing marijuana craving


Condition Intervention Phase
Marijuana Smoking
 Drug: Cesemat
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal

Resource links provided by NLM:

MedlinePlus related topics: Marijuana Smoking
Drug Information available for: Nabilone
U.S. FDA Resources

Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Safety and tolerability to Nabilone [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Marijuana craving questionnaire [ Designated as safety issue: No ]

Estimated Enrollment: 35
Study Start Date: June 2009
Study Completion Date: October 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cesemat Drug: Cesemat
1 mg capsule per day for 21 days
Other Name: Nabilone
No Intervention: Placebo

Detailed Description:

Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use

  Eligibility

Ages Eligible for Study:   19 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 19 years or older
  • History of marijuana use
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01025700

Locations
Canada, British Columbia
Vancouver General Hospital - Psychiatry Outpatient
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Investigators
Principal Investigator: Shaohua Lu, MD University of British Columbia
  More Information

No publications provided

Responsible Party: Shaohua Lu, MD, University of British Columbia
ClinicalTrials.gov Identifier: NCT01025700     History of Changes
Other Study ID Numbers: H08-01999
Study First Received: December 2, 2009
Last Updated: February 16, 2011
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
Efficacy
Marijuana
Reduction
Craving

Additional relevant MeSH terms:
Marijuana Abuse
Marijuana Smoking
Smoking
Substance-Related Disorders
Mental Disorders
Habits
Nabilone
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 16, 2013